How is orticumab differentiated from other anti-inflammatory therapies?
Current anti-inflammatory drugs take a systemic approach, affecting ubiquitous [...]
Dr. Peter Libby appointed to the Abcentra Board of Directors. Read the Article.
Current anti-inflammatory drugs take a systemic approach, affecting ubiquitous [...]
Orticumab recognizes and specifically binds a specific epitope of [...]